SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (1914)3/21/2002 1:12:09 AM
From: Spekulatius   of 10345
 
<< Let's take the company, piece by piece.>>
if you take out ELN's product acquisitions (250M$ for Y2002). ELN's revenue for Y2002 is about 1.25B$. (with out contract,Jv revenues etc etc.) Pharma companies with huge pipeline problems and patent expirations (BMY, SGP) trade at 5x revenues.
So for ELN I get 5 x1.25B$ =6.25B $ market cap equivalent to 18.5$/share. This is the absolute minimum. Normalized to the market cap, ELN's pipeline is much stronger than BMY and SGP's. ELN's liabilities are offset by cash on hand and LT investments - there is absolutely no way ELN can go bankrupt. Go figure!

[Disclosure]: Own a small position in ELN as of today (again)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext